Companies emerge from innovative technology, and EBI's technology productivity is very high. As of spring 2006, EBI intellectual property (IP) includes:

• One international patent
• Twenty-six U.S. patents
• Twenty-eight U.S. patent applications pending
• Thirteen active invention disclosures

This amounts to approximately 40% of current Ohio University IP. In addition, EBI's success metrics over the past decade include:

• Generating almost half of all OU intellectual property assets with less than 1% of OU's faculty
• Generating 95% of all OU licensing and royalty revenues
• Receiving 13% of all OU external research funding

This record of performance is a significant reason why Ohio University consistently ranks among the top academic institutions nationwide in technology productivity, according to surveys by the Association of University Technology Managers (AUTM).

Eight companies have been created through licensing of EBI "platform" technology. Six of these companies still exist, a testament to the value of our technologies.

Sensus
Sensus was the exclusive licensee of growth hormone antagonist (GHA) technology invented at EBI. After achieving success in Phase III clinical trials for acromegaly, the company was purchased by Pharmacia. In March 2003, Pharmacia received final US FDA approval for Somavert® (pegvisomant) just prior to its merger with Pfizer in April. Pfizer began selling the drug later the same year. Somavert, the first in a new class of medicines called growth hormone receptor antagonists, also has potential application in diabetic retinopathy and nephropathy and some forms of cancer.
Incorporated 1993

Copernicus
Copernicus Therapeutics, Inc. is a privately-held company developing products for human gene therapy and vaccination. Copernicus was established in 1997 based on Compacted Nucleic Acids (Plasmin™ complexes) technology that provides the foundation for the use of DNA as drugs.
Incorporated 1997

DNX
Originally called Embryogen, DNX was the exclusive commercial licensee of EBI's pronuclear microinjection technology, the most widely used method for producing transgenic animals. In November 2000, Xenogen Corp. acquired DNX Transgenic Sciences. Now called Xenogen Biosciences, this subsidiary of Xenogen provides transgenic technologies to the worldwide research community.
Embryogen incorporated 1984

DiAthegen
DiAthegen, LLC develops new diagnostics and therapeutics using genomic and animal models of obesity, hyperinsulinemea and diabetes. A major focus of the company’s research is a program of target discovery that relates changes in animal and human tissues to specific gene and protein changes over their progression from obesity to Type 2 diabetes. DiAthegen also is developing long-acting recombinant protein therapeutics. In April 2006, DiAthegen and Phyton Biotech announced an agreement for Phyton to commercialize DiAthegen’s long-acting growth hormone receptor antagonist.
Incorporated 2001

Interthyr
Interthyr Corp. (IC) works to develop improved cell-based diagnostic assays through genetic engineering, as well as new therapeutic products for autoimmune, endocrine and inflammatory diseases. In November 2003, IC and Diagnostic Hybrids Inc. (DHI) signed a four-year research and commercialization agreement with The University "Gd'Annunzio" to establish a new diagnostic lab service to detect autoimmune thyroid diseases.
Incorporated 1999

MetaCor
MetaCor Pharmaceuticals USA Inc. is a newly emerging therapeutics venture focused on a novel class of agents for treating diabetes, obesity, hyperlipidemia and immune disorders. The company holds exclusive rights to technology developed at EBI, and is preparing for clinical trials along with international partnerships for these and other indications, ahead of USA-based product development.
Incorporated 2003

Progenitor
Progenitor was founded on the basis of two technologies developed at EBI: isolation of hematopoietic stem cells and gene therapy vectors. In 1998, the company (PGEN) requested voluntary delisting of the company's common stock and warrants from the NASDAQ.
Incorporated 1992

Nextran
Nextran was formed as a joint venture between DNX and Baxter Healthcare. Baxter elected to suspend research operations at Nextran in 2003. That same year, Baxter donated Nextran's xenotransplantation program to the Mayo Clinic. Mayo, with whom Baxter had collaborated on the research since 1997, assumed full ownership of the program and will direct further related research.
Incorporated 1994